Aprea Therapeutics
APRE
41 hedge funds and large institutions have $10.4M invested in Aprea Therapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 9 closing their positions.
99% more call options, than puts
Call options by funds: $507K | Put options by funds: $255K
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
5% more funds holding
Funds holding: 39 → 41 (+2)
0.34% less ownership
Funds ownership: 1.18% → 0.84% (-0.34%)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
59% less capital invested
Capital invested by funds: $25.6M → $10.4M (-$15.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$1.92M |
| 2 |
Renaissance Technologies
New York
|
+$1.25M |
| 3 |
Morgan Stanley
New York
|
+$624K |
| 4 |
PP
PDT Partners
New York
|
+$242K |
| 5 |
VF
Virtu Financial
New York
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$6.44M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$591K |
| 4 |
BlackRock
New York
|
-$539K |
| 5 |
Goldman Sachs
New York
|
-$534K |
APRE Hedge Fund Activity: Q4 2021 in Review
41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2021, worth a combined $10.4M — down 59% from $25.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new APRE positions and 9 closed out — a net gain of 3 holders — while 9 added to existing stakes and 11 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $1.92M. The largest seller was Versant Venture Management, exiting entirely with an estimated $6.44M sold.
- 41 institutional investors held Aprea Therapeutics (APRE) as of Q4 2021, up from 39 in Q3 2021.
- Funds reported $10.4M of Aprea Therapeutics stock for Q4 2021, down 59% quarter-over-quarter.
- 12 funds opened new Aprea Therapeutics positions in Q4 2021 and 9 closed out, a net change of +3 holders.
- The largest Aprea Therapeutics buyer in Q4 2021 was Pura Vida Investments, an estimated $1.92M added.
- The largest Aprea Therapeutics seller in Q4 2021 was Versant Venture Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q4 2021.